Phase I Study of Paclitaxel (Taxol) and Bortezomib (Velcade) in Patients With Refractory Solid Tumor Malignancies Involving an Activated MAPK Pathway.
Phase of Trial: Phase I
Latest Information Update: 03 Jun 2014
At a glance
- Drugs Bortezomib; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 09 May 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov
- 15 Dec 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.